Cargando…

p53 protein is absent from the serum of patients with lung cancer.

p53 protein, which accumulates intracellularly in over half of all human tumours, has also been reported to be present in the sera of patients with various malignancies, including lung cancer. Using a quantitative immunoassay, we measured p53 protein concentrations in 216 sera from 114 lung cancer p...

Descripción completa

Detalles Bibliográficos
Autores principales: Levesque, M. A., D'Costa, M., Diamandis, E. P.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074762/
https://www.ncbi.nlm.nih.gov/pubmed/8912541
_version_ 1782138037557264384
author Levesque, M. A.
D'Costa, M.
Diamandis, E. P.
author_facet Levesque, M. A.
D'Costa, M.
Diamandis, E. P.
author_sort Levesque, M. A.
collection PubMed
description p53 protein, which accumulates intracellularly in over half of all human tumours, has also been reported to be present in the sera of patients with various malignancies, including lung cancer. Using a quantitative immunoassay, we measured p53 protein concentrations in 216 sera from 114 lung cancer patients of whom 75 provided matched lung tumour tissues, which were also assayed for p53 protein. p53 protein levels above the detection limit of 0.04 ng ml-1 were detected in only two sera from lung cancer patients (0.14 ng ml-1 and 0.27 ng ml-1), but not in any of 13 sera from non-malignant lung disease patients or in 100 sera from normal non-diseased individuals. The presence of these apparent traces of serum p53 protein concentrations could not be related either to the p53 protein expression status of the primary lung tumours or to the tumour stage, grade or histological type. By pretreating these two sera with anti-p53 antibody linked to solid phase, and by the addition of mouse serum to neutralise possible heterophilic antibodies, the signals arising from these sera were shown to be non-specific and possibly caused by heterophilic antibodies. We conclude that our data do not support previous reports of p53 protein in the sera of lung cancer patients. Since immunoassays are subject to numerous sources of interference in serum, including heterophilic antibodies, we suggest that the results of p53 protein analysis of serum specimens should be interpreted with caution.
format Text
id pubmed-2074762
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20747622009-09-10 p53 protein is absent from the serum of patients with lung cancer. Levesque, M. A. D'Costa, M. Diamandis, E. P. Br J Cancer Research Article p53 protein, which accumulates intracellularly in over half of all human tumours, has also been reported to be present in the sera of patients with various malignancies, including lung cancer. Using a quantitative immunoassay, we measured p53 protein concentrations in 216 sera from 114 lung cancer patients of whom 75 provided matched lung tumour tissues, which were also assayed for p53 protein. p53 protein levels above the detection limit of 0.04 ng ml-1 were detected in only two sera from lung cancer patients (0.14 ng ml-1 and 0.27 ng ml-1), but not in any of 13 sera from non-malignant lung disease patients or in 100 sera from normal non-diseased individuals. The presence of these apparent traces of serum p53 protein concentrations could not be related either to the p53 protein expression status of the primary lung tumours or to the tumour stage, grade or histological type. By pretreating these two sera with anti-p53 antibody linked to solid phase, and by the addition of mouse serum to neutralise possible heterophilic antibodies, the signals arising from these sera were shown to be non-specific and possibly caused by heterophilic antibodies. We conclude that our data do not support previous reports of p53 protein in the sera of lung cancer patients. Since immunoassays are subject to numerous sources of interference in serum, including heterophilic antibodies, we suggest that the results of p53 protein analysis of serum specimens should be interpreted with caution. Nature Publishing Group 1996-11 /pmc/articles/PMC2074762/ /pubmed/8912541 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Levesque, M. A.
D'Costa, M.
Diamandis, E. P.
p53 protein is absent from the serum of patients with lung cancer.
title p53 protein is absent from the serum of patients with lung cancer.
title_full p53 protein is absent from the serum of patients with lung cancer.
title_fullStr p53 protein is absent from the serum of patients with lung cancer.
title_full_unstemmed p53 protein is absent from the serum of patients with lung cancer.
title_short p53 protein is absent from the serum of patients with lung cancer.
title_sort p53 protein is absent from the serum of patients with lung cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074762/
https://www.ncbi.nlm.nih.gov/pubmed/8912541
work_keys_str_mv AT levesquema p53proteinisabsentfromtheserumofpatientswithlungcancer
AT dcostam p53proteinisabsentfromtheserumofpatientswithlungcancer
AT diamandisep p53proteinisabsentfromtheserumofpatientswithlungcancer